Home/Filings/4/0001104659-25-116066
4//SEC Filing

CK Life Sciences Intl (Holdings) Inc 4

Accession 0001104659-25-116066

CIK 0001818844other

Filed

Nov 24, 7:00 PM ET

Accepted

Nov 25, 5:39 PM ET

Size

18.4 KB

Accession

0001104659-25-116066

Insider Transaction Report

Form 4
Period: 2025-11-21
Sealbond Ltd
Director10% OwnerOther
Transactions
  • Conversion

    Common Stock

    2025-11-21+21,610,95021,822,333 total
  • Conversion

    Series A Preferred Stock

    2025-11-212,161.0950 total
    Common Stock (21,610,950 underlying)
  • Conversion

    Common Stock

    2025-11-21+2,842,6382,842,638 total(indirect: By Conjoint Inc.)
  • Conversion

    Series A-1 Preferred Stock

    2025-11-21284.2640 total(indirect: By Conjoint Inc.)
    Common Stock (2,842,638 underlying)
Transactions
  • Conversion

    Common Stock

    2025-11-21+21,610,95021,822,333 total
  • Conversion

    Common Stock

    2025-11-21+2,842,6382,842,638 total(indirect: By Conjoint Inc.)
  • Conversion

    Series A Preferred Stock

    2025-11-212,161.0950 total
    Common Stock (21,610,950 underlying)
  • Conversion

    Series A-1 Preferred Stock

    2025-11-21284.2640 total(indirect: By Conjoint Inc.)
    Common Stock (2,842,638 underlying)
Conjoint Inc.
Director10% OwnerOther
Transactions
  • Conversion

    Series A-1 Preferred Stock

    2025-11-21284.2640 total(indirect: By Conjoint Inc.)
    Common Stock (2,842,638 underlying)
  • Conversion

    Common Stock

    2025-11-21+2,842,6382,842,638 total(indirect: By Conjoint Inc.)
  • Conversion

    Common Stock

    2025-11-21+21,610,95021,822,333 total
  • Conversion

    Series A Preferred Stock

    2025-11-212,161.0950 total
    Common Stock (21,610,950 underlying)
Footnotes (4)
  • [F1]On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.
  • [F2]Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
  • [F3]Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
  • [F4]Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

Issuer

Dogwood Therapeutics, Inc.

CIK 0001818844

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001297567

Filing Metadata

Form type
4
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 5:39 PM ET
Size
18.4 KB